GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome

4/21/15–GW Pharma (GWPH +0.8%) initiates a Phase 3 study evaluating two doses of Epidiolex (cannabidiol), case 10 mg/kg and 20 mg/kg, and placebo in patients with Dravet syndrome, a rare and catastrophic form of childhood epilepsy. The 14-week trial will enroll 150 patients (50 patients per arm). The primary endpoint is the percentage change from baseline in convulsive seizure frequency during the maintenance period compared to placebo. Read